Prostate cancer is a type of cancer that affects a lot of men, and as there is no cure for cancer yet, spotting the symptoms is important. One of the possible indicators of the disease is through another condition, according to a new report.
Express reports that jaundice may also be a possible symptom of prostate cancer among men. Jaundice is referred to as having a yellowish tinge in the skin, as well as the whites of the eyes. This is caused by issues with the liver, and this condition would mean that the cancer has already progressed and spread towards the liver, where there may be some problems with the bile duct or large parts of the liver that have already been affected.
Jaundice is not the only indication that the cancer has already affected the liver. Other indicators include a pain on the right side of the body, nausea, loss of appetite, weight loss, itchy skin, as well as a swollen tummy.
Another possible indicator of prostate cancer is found in the urine. Express also reports that seeing a pink, red, or brownish-red color in the urine may be a symptom of prostate cancer. This would mean that there is blood. The same applies if there is blood in the semen, as the prostate is responsible for the production of semen, the fluid that is carrying the sperm. According to Cancer News Today, finding blood in the urine is also known as hematuria, and it can indicate that the prostate cancer has progressed.
However, because these are merely symptoms, there is a big chance that it may indicate other conditions that are not as severe as prostate cancer. Still, in case these are seen, then it is highly advised to consult a doctor to get a proper diagnosis and treatment. The earlier this is detected, the more successful treatment will be.
Prostate cancer mainly affects men above the age of 50, and the usual time of diagnosis between men is from 65 to 69. The risk of developing prostate cancer increases among men if there is a family history of either prostate or breast cancer.


Novartis to Acquire Avidity Biosciences for $12 Billion to Strengthen Rare Muscle Disorder Portfolio
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Pfizer Secures $10 Billion Deal for Obesity Drug Developer Metsera, Outbids Novo Nordisk
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths
Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Eli Lilly Becomes First Pharma Giant to Hit $1 Trillion Amid Soaring Weight-Loss Drug Demand
U.S. Backs Bayer in Supreme Court Battle Over Roundup Cancer Lawsuits
Pfizer Sues Novo Nordisk Over Alleged Tactics to Block Obesity Drug Competition
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores
Novo Nordisk Appoints Greg Miley as Global Head of Corporate Affairs Amid U.S. Pricing Pressure
U.S. Experts to Reassess Newborn Hepatitis B Vaccination Guidelines Amid Growing Debate
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 



